Government Caps Profit Margins on 137 Cancer Drugs at Thirty Percent

The central government has capped trade margins on 137 cancer medicines at thirty percent over the cost at the first point of sale. The affected drugs include patented medicines such as pembrolizumab, ribociclib, and abemaciclib.

New Price Rules

Manufacturers must submit their revised maximum retail prices to the National Pharmaceutical Pricing Authority within seven days. Market data analyzed by pricing authority experts showed that non-scheduled anti-cancer drugs carried an average trade mark-up of about 170 percent, with some mark-ups reaching 700 percent. The new price caps are expected to reduce maximum retail prices by 20 to 70 percent and save patients roughly 2,500 crore rupees annually.

Production And Compliance

Companies must maintain their current production levels and seek prior permission from the pricing authority before lowering average monthly output or stopping production. Any manufacturer that fails to comply will be required to deposit the overcharged amount along with interest. In cases where a drug's current maximum retail price is already lower than the newly calculated rate, companies must keep the lower price in place.

Context

Drug price control measures in India are implemented by authorities to make essential treatments accessible to patients who face high out-of-pocket medical expenses. High costs for specialized cancer therapies often create severe financial distress for families dealing with long-term medical care.